2026-05-27 · glp-1, medications, comparison, semaglutide, tirzepatide · 12 min read

Updated 2026-06-13

Which GLP-1 causes the most weight loss?

In the published phase 3 trials, tirzepatide (sold as Zepbound for obesity and Mounjaro for type 2 diabetes) produced the largest average weight loss. In SURMOUNT-1, adults on the 15 mg dose lost about 20–22% of body weight over 72 weeks. Semaglutide 2.4 mg (Wegovy) produced about 15% body weight loss over 68 weeks in STEP 1. Real-world results vary with dose, adherence, and lifestyle support, and trial averages are not guarantees.

What's the difference between Ozempic, Wegovy, Mounjaro, and Zepbound?

Ozempic and Wegovy are both semaglutide — Ozempic is FDA-approved for type 2 diabetes, Wegovy for chronic weight management at a higher dose. Mounjaro and Zepbound are both tirzepatide — Mounjaro is approved for type 2 diabetes, Zepbound for chronic weight management. So you're really comparing two molecules (semaglutide and tirzepatide) marketed under four brand names with different FDA-approved uses, dose ceilings, and insurance coverage.

Is tirzepatide stronger than semaglutide?

On average, yes — at the doses studied. Tirzepatide activates two gut hormone receptors (GLP-1 and GIP) instead of one, and head-to-head data in type 2 diabetes (SURPASS-2) showed greater weight reduction with tirzepatide than semaglutide. The first dedicated head-to-head obesity trial (SURMOUNT-5) reported in 2025 also favored tirzepatide. That said, individual response varies, and many people reach their goals on semaglutide.

Which GLP-1 is cheapest without insurance?

Without insurance, U.S. list prices for all four brands sit in the low four figures per month — Wegovy and Zepbound are typically around $1,000–$1,350, Ozempic and Mounjaro around $900–$1,100. Manufacturer direct-pay programs (such as Eli Lilly's vial program for Zepbound) have lowered out-of-pocket costs for some doses. Cost without insurance is similar across all four; the real cost difference usually comes from coverage and prior authorization.

Can I switch from one GLP-1 to another?

Yes, switching between GLP-1 medications is common and is done under clinician guidance. Your prescriber will choose a safe starting dose on the new drug based on your current dose, side effect history, and goals. You should not combine two GLP-1 medications, and you should not switch on your own. Reasons to switch include insurance changes, side effects, supply shortages, or a weight loss plateau.

Do I need diabetes to get a GLP-1 for weight loss?

No. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved specifically for chronic weight management in adults who meet BMI criteria — typically BMI ≥30, or BMI ≥27 with a weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol. Ozempic and Mounjaro are approved for type 2 diabetes and sometimes prescribed off-label for weight loss, though insurance rarely covers off-label use.

How much more weight do people lose on tirzepatide vs semaglutide on average?

In the SURMOUNT-5 head-to-head obesity trial published in 2025, tirzepatide produced meaningfully greater average weight loss than semaglutide over 72 weeks — roughly 20% body-weight loss with tirzepatide compared with about 14% with semaglutide. Individual results still vary widely, and many people reach their goals on semaglutide at its 2.4 mg maintenance dose. The trial averages narrow at lower tirzepatide doses; the largest gap shows up at the 15 mg dose.

How long do you have to stay on a GLP-1 to keep the weight off?

Most evidence points toward long-term, possibly indefinite use to maintain weight loss. In STEP-4 (semaglutide) and SURMOUNT-4 (tirzepatide), people who stopped the medication regained a large share of their lost weight within roughly one year, while those who continued maintained or kept losing. GLP-1s should be treated as ongoing therapy for a chronic condition rather than a finite course. Plan for sustained cost, monitoring, and lifestyle support, and discuss any dose changes or stops with your prescriber rather than self-tapering.

What's the difference between Ozempic and Wegovy specifically?

Ozempic and Wegovy are both semaglutide — the active ingredient is identical — but they are different brands with different FDA-approved uses and different maximum doses. Ozempic is approved for type 2 diabetes at doses up to 2.0 mg weekly. Wegovy is approved for chronic weight management at doses up to 2.4 mg weekly, and also for cardiovascular risk reduction in adults with cardiovascular disease and obesity or overweight. Insurance coverage typically follows the approved indication, so Wegovy is the on-label path for weight loss without diabetes.

GLP-1 Weight Loss Medications Compared (2026): Ozempic vs Wegovy vs Mounjaro vs Zepbound

Quick answer: Tirzepatide-based drugs (Mounjaro and Zepbound) produce the largest average weight loss in published trials — roughly 20% of body weight at the highest dose — while semaglutide-based drugs (Ozempic and Wegovy) are the longer-established option with about 15% average loss. The choice usually comes down to brand vs indication: Wegovy and Zepbound are FDA-approved for obesity, Ozempic and Mounjaro for diabetes. Insurance coverage, prior authorization rules, and dose ceiling drive most real-world decisions.

Quick stats

• Semaglutide (Wegovy 2.4 mg): average ~14.9% body-weight loss at 68 weeks in STEP-1.
• Tirzepatide (Zepbound 15 mg): average ~20.9% body-weight loss at 72 weeks in SURMOUNT-1.
• 2026 U.S. list price without insurance: roughly $1,000–$1,350 per month for Wegovy and Zepbound; about $900–$1,100 per month for Ozempic and Mounjaro. List prices change; manufacturer self-pay programs (e.g., Eli Lilly’s Zepbound vial program) can lower out-of-pocket cost.

If you are trying to compare GLP-1 weight loss medications, you are looking at two active ingredients — semaglutide and tirzepatide — sold under four brand names. This guide breaks down what is the same, what is different, and how clinicians actually choose between them. For background on the drug class, start with the GLP-1 weight loss overview.

If you are weighing GLP-1 medications against an operation, see bariatric surgery vs GLP-1 medications for an evidence-based head-to-head on expected loss, durability, and cost.

Side-by-side comparison

Trial averages are not promises. STEP 1 enrolled adults with obesity without diabetes; SURMOUNT-1 enrolled a similar population for tirzepatide. People with type 2 diabetes typically lose less weight on the same drug. Individual results depend on dose, adherence, lifestyle support, and biology.

Drug-by-drug summaries

Ozempic (semaglutide)

Ozempic is semaglutide marketed for type 2 diabetes. It is approved at doses up to 2.0 mg weekly, which is lower than the 2.4 mg used for Wegovy. In the SUSTAIN trials, Ozempic improved blood sugar control and produced modest weight loss — about 4 to 6 kg on average in diabetes populations.

Ozempic is widely prescribed off-label for weight loss in people without diabetes, but insurance typically only covers it for its diabetes indication. People prescribed Ozempic for weight loss often pay out of pocket, and the dose ceiling means they cap out below what Wegovy can reach.

The active ingredient is identical to Wegovy. The differences are dose, FDA labeling, and insurance pathway. For a focused look at how Ozempic and Wegovy compare, see Ozempic vs Wegovy, and for side effects see Ozempic side effects.

Wegovy (semaglutide)

Wegovy is the obesity-indication brand of semaglutide. It is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition — our BMI calculator will return your category and the healthy-weight range for your height if you want to check first. It is also approved for adolescents aged 12 and older with obesity — see adolescent and teen weight management for the AAP 2023 framework, the STEP TEENS evidence, and how pharmacotherapy fits inside family-based care — and for cardiovascular risk reduction in adults with cardiovascular disease and obesity or overweight.

In the STEP 1 trial published in the New England Journal of Medicine, adults on Wegovy 2.4 mg weekly lost about 15% of body weight at 68 weeks, compared with about 2.4% on placebo. STEP 4 showed that continued treatment was needed to maintain that loss — when people switched to placebo, they regained a substantial share.

Wegovy uses a slow titration schedule that takes roughly 4 to 5 months to reach the 2.4 mg maintenance dose. Most insurance plans require prior authorization, documented BMI, and prior lifestyle attempts. For the underlying active ingredient, see semaglutide for weight loss.

Mounjaro (tirzepatide)

Mounjaro is tirzepatide marketed for type 2 diabetes. Tirzepatide is unusual in this class because it activates both the GLP-1 and the GIP receptors — a dual agonist instead of a single agonist. In the SURPASS-2 trial, Mounjaro produced greater A1c reduction and greater weight loss than semaglutide 1 mg in people with type 2 diabetes.

Like Ozempic, Mounjaro is sometimes prescribed off-label for weight loss when Zepbound is not covered or available, but insurance coverage outside the diabetes indication is rare. The titration schedule and dose levels are the same as Zepbound (2.5 mg starting dose, maintenance options at 5, 10, or 15 mg weekly), and the molecule is identical.

People with type 2 diabetes who are also targeting weight loss sometimes prefer Mounjaro because a single prescription can address both goals and may have better coverage.

Zepbound (tirzepatide)

Zepbound is the obesity-indication brand of tirzepatide. It was approved by the FDA in late 2023 for chronic weight management in adults meeting standard BMI criteria, and in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity on the strength of the SURMOUNT-OSA trial — the first medication ever approved specifically for OSA in an obesity context.

In SURMOUNT-1, adults without diabetes on Zepbound 15 mg weekly lost about 20% of body weight at 72 weeks, compared with about 3% on placebo. The 5 mg and 10 mg doses produced about 15% and 19% loss respectively. SURMOUNT-2 showed smaller but still substantial loss in people with type 2 diabetes. In 2025, SURMOUNT-5 reported a direct head-to-head comparison favoring tirzepatide over semaglutide for weight loss in adults with obesity without diabetes.

Zepbound is the newest of the four brands, so long-term real-world data is still accumulating. Eli Lilly has also offered a direct-to-consumer vial program for some Zepbound doses, which can lower the out-of-pocket cost compared with the auto-injector pen.

Semaglutide vs tirzepatide: the active-ingredient story

The four brand names cover two distinct molecules.

Semaglutide is a GLP-1 receptor agonist. It mimics the hormone GLP-1, slowing stomach emptying, signaling fullness, and reducing food intake. It has been on the U.S. market since 2017 for diabetes and 2021 for obesity, so it has the longest post-approval safety record in this class.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates the GLP-1 receptor like semaglutide and adds activation of the GIP receptor, which is thought to contribute to additional appetite suppression and metabolic effects. The dual mechanism is the leading explanation for the larger average weight loss seen in tirzepatide’s phase 3 program.

For a deeper head-to-head on the active ingredients, see semaglutide vs tirzepatide.

How to choose between GLP-1 medications

A scannable decision framework for the most common situations:

• If maximum average weight loss is the priority and GI side effects are tolerable → tirzepatide (Zepbound) shows the largest average loss in published phase 3 trials, with about 20.9% body-weight loss at the 15 mg dose in SURMOUNT-1.
• If you have type 2 diabetes → both semaglutide and tirzepatide are FDA-approved; Ozempic and Mounjaro are the diabetes-indicated brands, and insurance coverage usually favors whichever your plan prefers on its formulary.
• If GI side effects have been intolerable on one drug → switching class members can help, but titration speed and dose usually matter more than the brand. Discuss a switch with your prescriber rather than self-adjusting; see Ozempic side effects for a deeper look at GI management.
• If insurance won’t cover branded GLP-1s and you’re considering compounded semaglutide → the FDA cautioned in 2024–2025 about sterility, dosing errors, and adverse events with compounded versions. Manufacturer self-pay programs (e.g., the Eli Lilly Zepbound vial program) are usually a safer route. See weight loss drug safety before going the compounded route.
• If you are considering sub-labeled compounded doses for cost or side-effect tolerance → our guide to GLP-1 sub-therapeutic microdosing protocols covers the three named protocols (quarter dose, eighth dose, pulsed), the proportional efficacy trade-off, and the 2026 legal and supply picture for compounded microdose semaglutide and tirzepatide.

Real-world factors clinicians weigh

There is no single “best” GLP-1. Most patients land on a drug for reasons that have little to do with the underlying molecule.

• Insurance and cost. Coverage drives most decisions. Many commercial plans cover one obesity-indication drug (Wegovy or Zepbound) but not the other. Medicare Part D does not currently cover GLP-1s for obesity alone, though it covers them for diabetes and for cardiovascular risk reduction in eligible patients. For 2026 pricing, manufacturer savings cards, LillyDirect vials, and step-by-step coverage checks, see GLP-1 cost and insurance coverage. Confirm formulary placement, prior authorization criteria, and step therapy requirements before settling on a drug.
• GI side effect tolerance. All GLP-1s share a similar GI profile — nausea, constipation, diarrhea, vomiting, especially during dose escalation. Slow titration and small, lower-fat meals help. If one drug produces intolerable nausea, clinicians sometimes switch to the other class member.
• Injection device preference. Wegovy and Ozempic use Novo Nordisk pen devices. Zepbound and Mounjaro use Eli Lilly pen devices, and Zepbound is also available in single-dose vials in some U.S. programs. Pen design matters more to some patients than others.
• Off-label realities. Ozempic and Mounjaro are FDA-approved for diabetes, so insurance coverage for weight loss alone is rare. Some clinicians still prescribe them off-label, but expect to pay out of pocket and to cap below the maintenance doses studied for obesity.
• When each is typically prescribed. A patient with type 2 diabetes plus obesity may end up on Ozempic or Mounjaro. A patient without diabetes meeting BMI criteria is more likely to be prescribed Wegovy or Zepbound. A patient with cardiovascular disease and obesity may be steered toward Wegovy for its FDA-approved cardiovascular indication. The 2024 ESSENCE (semaglutide) and SYNERGY-NASH (tirzepatide) trials added a new condition where these medications are clinically relevant — see fatty liver (NAFLD / MASLD) and weight loss for what the trials actually showed and how the drug data fits with lifestyle change.
• Hypertension as a coexisting target. Both classes produce 5 to 7 mmHg systolic drops at peak dose (STEP-1 and SURMOUNT-1), driven by the weight loss they produce. They are not stand-alone hypertension drugs, but they can meaningfully ease the BP medication burden in patients carrying both — see high blood pressure and weight loss.

For the broader landscape of approved options, see the prescription weight loss medications overview. If you are weighing medication against an operation, see bariatric surgery vs GLP-1 medications for an evidence-based side-by-side on expected loss, durability, and cost.

Safety and contraindications

All GLP-1 receptor agonists share a similar safety profile. The most important shared warnings:

• Boxed warning for thyroid C-cell tumors. All four drugs carry a boxed warning based on rodent studies. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
• Pancreatitis history. A prior episode of pancreatitis is a relative contraindication; discuss with your prescriber.
• Pregnancy and breastfeeding. These drugs are not recommended in pregnancy, while breastfeeding, or for people planning pregnancy in the near term. A washout period is recommended before conception.
• Gallbladder disease. Rapid weight loss raises the risk of gallstones; people with prior gallbladder disease should discuss risk with their clinician.
• Hypoglycemia risk. Mainly in people who also take insulin or sulfonylureas — dose adjustments may be needed for the other medications. See hypoglycemia and weight loss for symptoms, the 15-15 rule, and when to call a prescriber.
• GI side effects. Nausea, vomiting, constipation, and diarrhea are common, especially during titration. Dehydration from vomiting or diarrhea has been linked to acute kidney injury in some cases.

For a broader view of class safety, see weight loss drug safety, and for a deeper drug-specific look at side effects, see Ozempic side effects.

Frequently asked questions

Which GLP-1 causes the most weight loss? On published averages, tirzepatide (Zepbound at 15 mg) produced the largest loss — about 20–22% of body weight at 72 weeks in SURMOUNT-1 — followed by Wegovy at about 15% in STEP 1. Individual results vary, and the highest dose is not always the right dose for a given person.

What’s the difference between Ozempic, Wegovy, Mounjaro, and Zepbound? Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are both tirzepatide. Within each pair, the difference is FDA-approved use (diabetes vs obesity), dose ceiling, and insurance pathway. The molecules within each pair are identical.

Is tirzepatide stronger than semaglutide? At the doses studied, yes on average. SURPASS-2 in diabetes and SURMOUNT-5 in obesity both showed greater weight reduction with tirzepatide. The dual GIP/GLP-1 mechanism is the leading explanation. Individual results still vary widely.

Which is cheapest without insurance? U.S. list prices for all four sit in the low four figures per month. Manufacturer direct-pay vial programs (such as the Eli Lilly Zepbound vial program) have made some doses cheaper than auto-injector pens. Cost without insurance is broadly similar across all four; the real difference comes from coverage.

Can I switch from one GLP-1 to another? Yes, under clinician guidance. Reasons include insurance changes, intolerable side effects, supply shortages, or a plateau. Never combine two GLP-1 medications, and do not switch on your own — your prescriber will choose a safe starting dose on the new drug.

Can I take a GLP-1 if I don’t have diabetes? Yes. Wegovy and Zepbound are FDA-approved specifically for chronic weight management in adults meeting BMI criteria. Ozempic and Mounjaro are diabetes drugs and are sometimes used off-label, though insurance rarely covers that use.

How much more weight do people lose on tirzepatide vs semaglutide on average? In SURMOUNT-5, the first dedicated head-to-head obesity trial published in 2025, adults on tirzepatide lost about 20% of body weight at 72 weeks compared with about 14% on semaglutide. The gap is largest at tirzepatide’s 15 mg dose and narrower at lower doses. Many people still reach their goals on semaglutide; the trial average is not a personal forecast.

How long do you have to stay on a GLP-1 to keep the weight off? Most current evidence points toward long-term, possibly indefinite use. In STEP-4 and SURMOUNT-4, people who stopped semaglutide or tirzepatide regained a large share of their lost weight within about a year, while those who continued maintained or kept losing. Treat these drugs as ongoing therapy for a chronic condition rather than a finite course, and plan for sustained cost, monitoring, and lifestyle support. For the trial-by-trial regain numbers, a stop-vs-taper-vs-maintenance-dose comparison, and the five levers that meaningfully change the regain curve, see rebound weight gain after stopping GLP-1.

What’s the difference between Ozempic and Wegovy specifically? The active ingredient is the same — semaglutide. The differences are FDA-approved use (Ozempic for type 2 diabetes; Wegovy for chronic weight management, and for cardiovascular risk reduction in eligible adults with obesity or overweight), maximum dose (2.0 mg/wk for Ozempic vs 2.4 mg/wk for Wegovy), and insurance pathway. For weight loss without diabetes, Wegovy is the on-label brand and is usually the easier coverage path.

Sources